KNSA Key Statistics, Chart & Performance
The current stock price of KNSA is 41.12 USD. In the past month the price increased by 0.27%. In the past year, price increased by 121.79%.
KNSA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.28 | 388.89B | ||
| AMGN | AMGEN INC | 14.89 | 175.30B | ||
| GILD | GILEAD SCIENCES INC | 14.97 | 152.11B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.53 | 116.86B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.06 | 80.72B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 727.27 | 49.00B | ||
| INSM | INSMED INC | N/A | 35.77B | ||
| NTRA | NATERA INC | N/A | 32.49B | ||
| BIIB | BIOGEN INC | 11.09 | 27.23B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 22.65B | ||
| INCY | INCYTE CORP | 16.56 | 20.87B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.28 | 20.77B |
Related stock screener links
About KNSA
Company Profile
Kiniksa Pharmaceuticals International Plc is a commercial-stage biopharmaceutical company. Its portfolio of assets is based on strong biologic rationale or validated mechanisms and offers the potential for differentiation. Its ARCALYST is used for the treatment of recurrent pericarditis and reduces the risk of recurrence in adults and children 12 years and older. ARCALYST is also approved for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome, and the maintenance of remission in Deficiency of Interleukin-1 Receptor Antagonist. Its other portfolio includes KPL-387, KPL-1161, Abiprubart, and Mavrilimumab. Mavrilimumab is an investigational monoclonal antibody inhibitor targeting granulocyte-macrophage colony stimulating factor receptor alpha.
Company Info
KINIKSA PHARMACEUTICALS INTE
23 Old Bond Street, Floor 3
London HM11 GB
CEO: Sanj K. Patel
Employees: 315
KINIKSA PHARMACEUTICALS INTE / KNSA FAQ
Can you describe the business of KINIKSA PHARMACEUTICALS INTE?
Kiniksa Pharmaceuticals International Plc is a commercial-stage biopharmaceutical company. Its portfolio of assets is based on strong biologic rationale or validated mechanisms and offers the potential for differentiation. Its ARCALYST is used for the treatment of recurrent pericarditis and reduces the risk of recurrence in adults and children 12 years and older. ARCALYST is also approved for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome, and the maintenance of remission in Deficiency of Interleukin-1 Receptor Antagonist. Its other portfolio includes KPL-387, KPL-1161, Abiprubart, and Mavrilimumab. Mavrilimumab is an investigational monoclonal antibody inhibitor targeting granulocyte-macrophage colony stimulating factor receptor alpha.
Can you provide the latest stock price for KINIKSA PHARMACEUTICALS INTE?
The current stock price of KNSA is 41.12 USD. The price decreased by -3.63% in the last trading session.
What is the dividend status of KINIKSA PHARMACEUTICALS INTE?
KNSA does not pay a dividend.
What is the ChartMill technical and fundamental rating of KNSA stock?
KNSA has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
What do analysts say about KINIKSA PHARMACEUTICALS INTE (KNSA) stock?
13 analysts have analysed KNSA and the average price target is 55.81 USD. This implies a price increase of 35.72% is expected in the next year compared to the current price of 41.12.
Can you provide the number of employees for KINIKSA PHARMACEUTICALS INTE?
KINIKSA PHARMACEUTICALS INTE (KNSA) currently has 315 employees.
Can you provide the market cap for KINIKSA PHARMACEUTICALS INTE?
KINIKSA PHARMACEUTICALS INTE (KNSA) has a market capitalization of 3.12B USD. This makes KNSA a Mid Cap stock.
KNSA Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to KNSA. When comparing the yearly performance of all stocks, KNSA is one of the better performing stocks in the market, outperforming 94.43% of all stocks.
KNSA Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to KNSA. KNSA is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average.
KNSA Financial Highlights
Over the last trailing twelve months KNSA reported a non-GAAP Earnings per Share(EPS) of 0.45. The EPS increased by 421.43% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 6.01% | ||
| ROA | 5.04% | ||
| ROE | 6.71% | ||
| Debt/Equity | 0 |
KNSA Forecast & Estimates
13 analysts have analysed KNSA and the average price target is 55.81 USD. This implies a price increase of 35.72% is expected in the next year compared to the current price of 41.12.
For the next year, analysts expect an EPS growth of 263.59% and a revenue growth 59.08% for KNSA